Determine the effect of supplementation with selenium on gene function in patients with metabolic syndrome in the presence of cardiovascular disease

Determine the effect of supplementation with selenium on performance SEPP1 genes and gene level SELS, mRNA and protein in the presence of cardiovascular disease in patients with metabolic syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016012122134N2

Enrollment

150

Registered

2016-02-21

Start date

2014-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Metabolic syndrome. Condition 2: cardiovascular disease. Endocrine, nutritional and metabolic diseases Cardiovascular accident NOS

Interventions

Intervention 1: The first group (intervention group) 200 mcg Selenium for 8 weeks. Intervention 2: The second group (control) placebo for 8 weeks.

Treatment - Drugs

The first group (intervention group) 200 mcg Selenium for 8 weeks

The second group (control) placebo for 8 weeks

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria include: a desire to participate in the study; age range 40 to 60 years; residence of Isfahan; not having any diseases: including diseases of liver; kidney; gout and rheumatoid arthritis; thyroid disorders; adrenal; parathyroid; gynecology; cancer; heart disease; arrhythmias; uncontrolled of CHF; valvular disease; severe pericarditis and myocarditis. Exclusion criteria included: pregnancy and lactation, liver disease, kidney disease, glucocorticoid therapy, hormone therapy, Cushing's syndrome, inflammatory bowel disease and other inflammatory disorders, gastrointestinal disease and lactose intolerance, selenium supplementation, taking antacids, chemotherapy, corticosteroids, statins, niacin and contraceptives.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
SEPS Gene. Timepoint: Before and after 8 weeks. Method of measurement: PCR RFLP.;SELS Gene. Timepoint: Before and after 8 weeks. Method of measurement: PCR RFLP.	—

Secondary

Measure	Time frame
Weight. Timepoint: Before and after 8 weeks. Method of measurement: scale.;Waist. Timepoint: Before and after 8 weeks. Method of measurement: Meter.;Blood pressure. Timepoint: Before and after 8 weeks. Method of measurement: manometer.;History of smoking. Timepoint: Before and after 8 weeks. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojgan Gharipour

Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Iran

mojgangharipour@gmail.com+98 313359090

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026